Teva Pharmaceutical: Buy This Bargain Before It’s Gone


  • Since Richard Francis became CEO in early 2023, his ‘Pivot to Growth’ strategy has continued to bear fruit.
  • On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter of 2024.
  • Austedo/Austedo XR sales totaled $282 million in the first three months of 2024, up 65.9% yearly, thanks to its competitive advantage in the fast-growing tardive dyskinesia therapeutics market.
  • The company has an extensive portfolioof experimental medications aimed at treating schizophrenia, Crohn’s disease,multiple system atrophy, Parkinson’s disease, and more.
  • Consequently, I’m initiating coverageof TevaPharmaceutical with a”buy” rating.

Woman taking vitamins and supplements.

Guido Mieth

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Israel’s largest pharmaceutical company and one of the major suppliers of generic drugs in the United States and the European Union.

Investment thesis

Over the past year, the company has made tremendous progress

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *